For the many cancer patients whose treatment is quietly undermined not by the disease itself but by the body's response to its cure, a small oral pill may represent a meaningful turning point. A phase 2 trial published in the Journal of Clinical Oncology found that avatrombopag, given to gastrointestinal cancer patients suffering from chemotherapy-induced low platelet counts, allowed 70 percent to remain on their full treatment schedule — compared to just 17 percent on placebo. In a field where no approved remedy for this complication has existed, the finding speaks to how often the margin bet
Avatrombopag Keeps Cancer Patients on Chemo Schedule in Phase 2 Trial
Chemotherapy-induced thrombocytopenia delays or reduces cancer treatment doses, potentially compromising patient survival outcomes.
Chemotherapy remains the backbone of treatment for gastrointestinal cancers
Mark
Why does chemotherapy wreck platelet counts in the first place?
Mimi
Chemotherapy is a blunt instrument—it kills fast-dividing cells, which is what cancer cells are. But bone marrow, where platelets are made, also divides fast. So the drug damages the factory that makes the blood cells you need to clot and stop bleeding.
Mark
And when platelets drop, what actually happens to the patient?
Mimi
Bleeding becomes a real risk. A small cut won't stop. Nosebleeds, bruising, internal bleeding—all become dangerous. So doctors have to pause chemotherapy until the counts recover, or give transfusions. Either way, the cancer gets a reprieve.
Mark
So avatrombopag somehow tells the bone marrow to make more platelets?
Mimi
Essentially, yes. It's a thrombopoietin receptor agonist—it signals the body to produce more platelets. It's oral, so patients take a pill instead of needing infusions. That matters for quality of life.
Mark
Seventy percent stayed on schedule. What about the other 30 percent?
Mimi
They still had persistent low counts despite the drug. We don't yet know why some people respond and others don't. That's the next question.
Mark
Does this change how oncologists will treat these patients?
Mimi
Not yet. This is phase 2—proof it works. Phase 3 will be larger, more rigorous. If that succeeds, then yes, it becomes standard. But the door is open now.
O Pulso
- Chemotherapy-induced thrombocytopenia silently derails thousands of cancer treatments each year, forcing doctors to pause, reduce, or abandon the very regimens patients depend on to survive.
- With no approved drug to address the problem, patients have faced an impossible bind: endure dangerous platelet drops or accept a weakened treatment that gives cancer more room to advance.
- A phase 2 trial across four U.S. cancer centers tested avatrombopag against placebo in 47 gastrointestinal cancer patients — and the results were compelling enough that an ethics board halted the trial early to give all patients access to the drug.
- Eighty-three percent of patients on avatrombopag recovered safe platelet levels, none required blood transfusions, and no serious side effects were recorded.
- The drug has not yet been proven to extend long-term survival, and larger studies are needed — but for patients watching their treatment schedules collapse around falling blood counts, it offers the first real clinical foothold.
For the many cancer patients whose treatment is quietly undermined not by the disease itself but by the body's response to its cure, a small oral pill may represent a meaningful turning point. A phase 2 trial published in the Journal of Clinical Oncology found that avatrombopag, given to gastrointestinal cancer patients suffering from chemotherapy-induced low platelet counts, allowed 70 percent to remain on their full treatment schedule — compared to just 17 percent on placebo. In a field where no approved remedy for this complication has existed, the finding speaks to how often the margin between survival and setback is measured not in tumors, but in the quiet arithmetic of blood counts and missed appointments.
When chemotherapy attacks cancer, it often attacks platelets too — the cells that prevent uncontrolled bleeding. This side effect, chemotherapy-induced thrombocytopenia, is common enough to derail treatment in thousands of patients annually, forcing doctors to pause infusions, cut doses, or resort to transfusions. Until now, no approved medication existed to address it.
A phase 2 trial led by researchers at Mass General Brigham Cancer Institute tested an oral drug called avatrombopag in 47 adults with gastrointestinal cancers who had developed persistent low platelet counts during chemotherapy. The results were stark: 70 percent of those receiving avatrombopag stayed on their full treatment schedule without delays or dose reductions, compared to just 17 percent on placebo. The independent monitoring board stopped the trial early — continuing to give some patients a placebo had become ethically untenable.
Platelet counts recovered to safe levels in 83 percent of the treatment group, versus 46 percent in the placebo group. No patients on avatrombopag required blood transfusions, and no serious side effects were attributed to the drug. Lead researcher Hanny Al-Samkari, a hematologist at Mass General Brigham, noted that keeping patients on schedule matters enormously — every delay or dose reduction gives the cancer more time and space.
The trial is a proof of concept, not a final answer. Whether improved platelet management translates into better long-term survival will require larger, longer studies. But for patients dreading the call that their next treatment has been postponed, avatrombopag offers something that has been absent from oncology's toolkit: a real option to keep moving forward.
When chemotherapy destroys cancer cells, it often destroys something else too: the platelets that keep blood from bleeding uncontrollably. This side effect, called chemotherapy-induced thrombocytopenia, is common enough that it derails treatment in thousands of patients every year. Doctors have to pause chemotherapy, reduce doses, or transfuse platelets—all of which compromise the very thing the patient came for: a chance at cure. Until now, there has been no approved medication to fix it.
A phase 2 trial led by researchers at Mass General Brigham Cancer Institute has found that an oral drug called avatrombopag can change that equation. In a study of 47 adults with gastrointestinal cancers who developed persistent low platelet counts during treatment, 70 percent of those given avatrombopag stayed on their full chemotherapy schedule without delays or dose cuts. Among those given placebo, only 17 percent managed the same. The work, published in the Journal of Clinical Oncology, suggests a straightforward intervention that could keep cancer patients moving forward through their treatment.
The trial enrolled patients from four cancer centers across the United States, ranging in age from 25 to 84. Thirty percent were women; 17 percent identified as non-White; 11 percent as Hispanic or Latino. Researchers randomly assigned them to receive either avatrombopag or placebo and watched what happened to their platelet counts and their ability to continue chemotherapy on schedule. The results were striking enough that an independent monitoring board stopped the trial early—the drug was working so well that continuing to give some patients a placebo became ethically difficult to justify.
The numbers tell the story clearly. Among patients who received avatrombopag, 83 percent saw their platelet counts recover to safe levels. In the placebo group, 46 percent recovered on their own. More importantly, the drug allowed patients to keep their chemotherapy appointments and doses intact. No serious side effects were attributed to avatrombopag, and no patients in the treatment group needed blood transfusions—a significant finding because transfusions carry their own risks and costs.
Hanny Al-Samkari, the lead researcher and a hematologist at Mass General Brigham, framed the stakes plainly: chemotherapy remains the backbone of treatment for gastrointestinal cancers, and patients need to stay on course. When low platelet counts force delays or reductions, the cancer often has more time to grow, and survival odds shift. "This has historically been a very challenging complication to manage," Al-Samkari said. Now there may be a tool that actually works.
The trial is a proof of concept, not yet a finished story. Researchers acknowledge that showing avatrombopag can restore platelet counts and keep patients on schedule is one thing; proving it actually improves long-term survival is another. That work will take time and larger studies. But for patients sitting in an oncology chair, watching their blood counts drop and dreading the call that their next treatment is postponed, this result offers something that has been missing: a real option to keep moving forward.
Citações Notáveis
Chemotherapy remains a cornerstone of therapy for gastrointestinal cancers, so we want patients to be able to stay on their planned treatment.— Dr. Hanny Al-Samkari, lead researcher, Mass General Brigham Cancer Institute
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine